The Beninese Health Agency (ABMed) ordered the quarantine of all batches of TOCFIM on 23 October 2026. This product is a 100 mg/5 mL oral suspension of Cefixime distributed in 60 mL bottles. Acton Pharma Pvt. Ltd. Markets the antibiotic medication within Bénin. Authorities identified the drug as the subject of the immediate safety measure to restrict distribution. The ABMed ordered the quarantine of all batches of TOCFIM, a 100 mg/5 mL oral suspension of Cefixime in 60 mL bottles, as part of a formal administrative directive. TOCFIM is marketed by the laboratory Acton Pharma Pvt. Ltd.
Medical Use and Indications
TOCFIM functions as a third-generation cephalosporin antibiotic. Clinicians prescribe the medication for the treatment of pediatric infections, specifically targeting cases of otitis, bronchitis, pneumonia, and urinary tract infections. TOCFIM is a third-generation cephalosporin antibiotic used for pediatric infections including otitis, bronchitis, pneumonia, and urinary tract infections. The pharmaceutical product is formulated specifically for oral administration in pediatric patients who require this specific class of cephalosporin therapy.
A previous regulatory action involved the targeted withdrawal of a single batch of TOCFIM on 16 June 2026. A previous targeted withdrawal of a single batch of TOCFIM occurred on June 16, 2026. That specific event preceded the current full quarantine order issued by the Beninese Health Agency (ABMed). The regulatory history of the product now includes both the localized withdrawal of the single batch earlier in the year and the current, more expansive mandate covering all distributed batches of the medication.
The ABMed is currently conducting investigations into the quality of the product. The ABMed is conducting investigations into the quality of the product. These assessments aim to determine the safety profile of the antibiotic medication marketed by Acton Pharma Pvt. Ltd. Within Bénin. Agency officials are reviewing the manufacturing and distribution standards associated with the product to ensure compliance with health regulations. The scope of the investigation covers the chemical and physical properties of the 100 mg/5 mL oral suspension.
As the investigation continues, the Beninese Health Agency (ABMed) has maintained the requirement that all batches of TOCFIM remain under quarantine status. This measure prevents the further circulation of the antibiotic while the laboratory findings are finalized. Acton Pharma Pvt. Ltd. Remains the primary point of contact for the distribution of the product within the country. The agency has indicated that the objective of these ongoing assessments is to verify the quality of the medication. All relevant data regarding the 60 mL bottles of the antibiotic are being processed by the agency’s technical departments. The current quarantine remains in effect until the investigation into the quality of the product is concluded by the Beninese Health Agency (ABMed).
